Opus Genetics (NASDAQ:IRD) Insider Rabourn Amy Zaremba Sells 2,816 Shares of Stock

Opus Genetics, Inc. (NASDAQ:IRD) insider Rabourn Amy Zaremba sold 2,816 shares of the stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $5.25, for a total transaction of $14,784.00. Following the completion of the transaction, the insider directly owned 190,312 shares of the company’s stock, valued at approximately $999,138. The trade was a 1.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Opus Genetics Trading Down 4.0%

Opus Genetics stock traded down $0.19 during trading hours on Thursday, hitting $4.48. 327,179 shares of the stock traded hands, compared to its average volume of 993,493. Opus Genetics, Inc. has a one year low of $0.65 and a one year high of $5.30. The firm’s 50-day moving average price is $3.35 and its two-hundred day moving average price is $2.41. The company has a market cap of $318.40 million, a PE ratio of -5.41 and a beta of 0.45.

Wall Street Analysts Forecast Growth

IRD has been the topic of several recent research reports. BTIG Research upped their price target on Opus Genetics from $7.00 to $12.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. B. Riley Financial began coverage on Opus Genetics in a research report on Wednesday, December 10th. They issued a “buy” rating and a $9.00 price target on the stock. Craig Hallum set a $9.00 price objective on Opus Genetics and gave the company a “buy” rating in a research note on Wednesday, March 11th. Wedbush increased their target price on Opus Genetics from $8.00 to $10.00 and gave the stock an “outperform” rating in a research note on Thursday, March 12th. Finally, Wall Street Zen upgraded Opus Genetics from a “sell” rating to a “hold” rating in a report on Sunday, March 1st. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $9.33.

Institutional Investors Weigh In On Opus Genetics

A number of institutional investors have recently made changes to their positions in IRD. Nantahala Capital Management LLC increased its position in shares of Opus Genetics by 42.9% during the fourth quarter. Nantahala Capital Management LLC now owns 4,781,330 shares of the company’s stock valued at $9,610,000 after acquiring an additional 1,435,407 shares in the last quarter. BIOS Capital Management LP raised its holdings in Opus Genetics by 270.1% in the 2nd quarter. BIOS Capital Management LP now owns 3,683,429 shares of the company’s stock worth $3,462,000 after acquiring an additional 2,688,180 shares during the last quarter. Balyasny Asset Management L.P. bought a new position in Opus Genetics in the 4th quarter valued at approximately $5,463,000. Millennium Management LLC purchased a new stake in Opus Genetics during the 4th quarter valued at $4,025,000. Finally, Mink Brook Asset Management LLC boosted its stake in Opus Genetics by 34.5% during the 4th quarter. Mink Brook Asset Management LLC now owns 1,665,631 shares of the company’s stock valued at $3,348,000 after purchasing an additional 427,684 shares during the last quarter. Hedge funds and other institutional investors own 14.97% of the company’s stock.

Key Headlines Impacting Opus Genetics

Here are the key news stories impacting Opus Genetics this week:

• Positive Sentiment: Multiple analysts initiated/raised coverage with bullish ratings and higher price targets (Oppenheimer started coverage with an “outperform” and $10 target; Wedbush and BTIG recently raised targets and maintained buy/outperform views), giving the stock upside potential versus current levels. Article Title
• Neutral Sentiment: Institutional ownership movements show recent inflows from several funds (BIOS Capital, Voss Capital, Wells Fargo, State Street increased positions), which may support longer-term demand but have unclear timing impact on the share price. Article Title
• Neutral Sentiment: Liquidity and technicals: today’s volume is below the stock’s average (indicating lower trading interest), while the 50-day ($3.35) and 200-day ($2.41) moving averages and the 12‑month range ($0.65–$5.30) provide context for support/resistance levels. Article Title
• Negative Sentiment: Cluster of insider selling on March 16 — CEO George Magrath sold 24,438 shares (~$127k at ~$5.21), Ashwath Jayagopal sold 3,719 shares, COO Joseph K. Schachle sold 3,719 shares, and Amy Zaremba Rabourn sold 2,816 shares. These disclosures (filed with the SEC) represent modest reductions in insider stakes and are likely a principal driver of near-term downward pressure on the stock. Insider Trades CEO Form 4

About Opus Genetics

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.